These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 22716658)
1. IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse. Kostek MC; Nagaraju K; Pistilli E; Sali A; Lai SH; Gordon B; Chen YW BMC Musculoskelet Disord; 2012 Jun; 13():106. PubMed ID: 22716658 [TBL] [Abstract][Full Text] [Related]
2. Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-6 receptor antibodies and urocortin-2. Burns DP; Canavan L; Rowland J; O'Flaherty R; Brannock M; Drummond SE; O'Malley D; Edge D; O'Halloran KD J Physiol; 2018 Nov; 596(21):5175-5197. PubMed ID: 30160301 [TBL] [Abstract][Full Text] [Related]
3. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice. Wada E; Tanihata J; Iwamura A; Takeda S; Hayashi YK; Matsuda R Skelet Muscle; 2017 Oct; 7(1):23. PubMed ID: 29078808 [TBL] [Abstract][Full Text] [Related]
4. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992 [TBL] [Abstract][Full Text] [Related]